YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells
Version 2 2024-06-06, 01:30
Version 1 2015-03-19, 15:03
journal contribution
posted on 2024-06-06, 01:30 authored by SM Cheng, YC Chang, CY Liu, JY Lee, HH Chan, CW Kuo, KY Lin, SL Tsai, SH Chen, CF Li, E Leung, JR Kanwar, CC Huang, JY Chang, CH CheungThe aim of this study was to determine the potency and molecular mechanism of action of YM155, a first-in-class survivin inhibitor that is currently under phase I/II clinical investigations, in various drug-resistant breast cancers including the oestrogen receptor positive (ER(+) ) tamoxifen-resistant breast cancer and the caspase-3-deficient breast cancer.
History
Journal
British journal of pharmacologyVolume
172Pagination
214-234Location
London, Eng.Publisher DOI
Open access
- Yes
eISSN
1476-5381Language
engPublication classification
C Journal article, C1 Refereed article in a scholarly journalCopyright notice
2015, John Wiley & SonsIssue
1Publisher
WileyUsage metrics
Keywords
Science & TechnologyLife Sciences & BiomedicinePharmacology & PharmacySMALL-MOLECULE SUPPRESSORPHASE-IICONCISE GUIDETAMOXIFEN RESISTANCEHORMONE-RECEPTORSPHARMACOLOGYAPOPTOSISEXPRESSIONP62/SQSTM1RECURRENCESchool of Medicine111299 Oncology and Carcinogenesis not elsewhere classified920102 Cancer and Related Disorders929999 Health not elsewhere classified111204 Cancer Therapy (excl Chemotherapy and Radiation Therapy)
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC